局部进展期胃癌新辅助化疗两药与三药方案的比较

目的 探讨局部进展期胃癌患者不同新辅助化疗方案的疗效及影响预后的因素.方法 选取2006年12月至2013年5月间中国医学科学院肿瘤医院收治的接受新辅助化疗并进行手术切除的157例胃癌患者.回顾性分析患者的临床资料,根据治疗方法 不同进行分组.其中,采用奥沙利铂或顺铂联合卡培他滨或替吉奥或氟尿嘧啶两药治疗的90例患者纳...

Comparison of dual and triple neoadjuvant chemotherapy for locally advanced gastric cancer

Objective To evaluate the efficacy of different neoadjuvant chemotherapy regimens and the factors influencing the prognosis in patients with locally advanced gastric cancer. Methods A total of157 patients with locally advanced gastric cancer who received neoadjuvant chemotherapy and underwent surgical resection at Cancer Hospital,Chinese Academy of Medical Sciences were selected between December 2006 and May 2013 were selected. Their clinical data were restrospectively analyzed and they were divided into different groups based on the treatment they received. Ninety patients receiving oxaliplatin or cisplatin plus capecitabine or tegafur were included in the dual regimen group and 67 patients receiving platinum-based dual therapy plus paclitaxel or docetaxel or epirubicin were included in the triple regimen group.Pathological complete remission( PCR) rate,R0 resection rate,pathological remission rate and survival time were compared between the two groups and factors influencing the progosis were analyzed. The key factors influencing the overall survival( OS) and disease-free survival( DFS) were discussed. Results The major pathologic response( MPR) rate was higher in the triple regimen group than in the dual regimen group( all P <0. 05). There was no significant difference in PCR,R0,resection rate,DFS and OS between the two groups( P > 0. 05). Multivariate analysis showed non-R0 resection was an independent factor influencing OS( P < 0. 05). Conclusion Increasing treatment intensity of neoadjuvant chemotherapy does not improve DFS and 0 S in locally advanced gastric cancer. New neoadjuvant chemotherapy should be explored.